STOCK TITAN

[Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD): CEO/Chairman Quang Pham reported open‑market sales under a Rule 10b5‑1 plan. On 10/24/2025, he sold 1,129 shares of common stock at a weighted average price of $14.03, with trades ranging from $13.99 to $14.10. On 10/27/2025, he sold 1,315 shares at a weighted average price of $13.99, with trades ranging from $13.99 to $14.00. The trading arrangement was adopted on May 9, 2025.

Following these transactions, direct beneficial ownership was 197,404 shares after the first sale and 196,089 shares after the second. He also holds 200,000 shares indirectly through The PVBQ Living Trust, for which he serves as trustee with sole voting and disposition power.

Cadrenal Therapeutics (CVKD): il CEO/presidente Quang Pham ha riferito vendite in mercato aperto secondo un piano Rule 10b5-1. Il 24/10/2025 ha venduto 1.129 azioni ordinarie a prezzo medio ponderato di 14,03 dollari, con operazioni comprese tra 13,99 e 14,10. Il 27/10/2025 ha venduto 1.315 azioni a prezzo medio ponderato di 13,99 dollari, con operazioni tra 13,99 e 14,00. L'accordo di negoziazione è stato adottato il 9 maggio 2025.

A seguito di queste transazioni, la proprietà diretta beneficiaria era di 197.404 azioni dopo la prima vendita e 196.089 azioni dopo la seconda. Possiede inoltre 200.000 azioni indirettamente attraverso The PVBQ Living Trust, di cui è fiduciario con potere di voto e disposizione esclusivo.

Cadrenal Therapeutics (CVKD): el CEO/presidente Quang Pham reportó ventas en el mercado abierto bajo un plan Rule 10b5-1. El 24/10/2025 vendió 1.129 acciones ordinarias a un precio medio ponderado de 14,03 dólares, con operaciones entre 13,99 y 14,10. El 27/10/2025 vendió 1.315 acciones a un precio medio ponderado de 13,99 dólares, con operaciones entre 13,99 y 14,00. El régimen de negociación se adoptó el 9 de mayo de 2025.

Después de estas transacciones, la titularidad directa beneficiosa fue de 197.404 acciones tras la primera venta y 196.089 acciones tras la segunda. También posee 200.000 acciones indirectamente a través de The PVBQ Living Trust, del cual es fideicomisario con poder de voto y disposición exclusivo.

Cadrenal Therapeutics (CVKD): CEO 겸 의장 Quang Pham은 Rule 10b5-1 계획에 따른 공개시장 매도를 보고했습니다. 2025년 10월 24일에 보통주 1,129주를 가중평균가 14.03달러로 매도했으며 체결가 범위는 13.99~14.10달러였습니다. 2025년 10월 27일에는 1,315주를 가중평균가 13.99달러로 매도했고 체결가 범위는 13.99~14.00달러였습니다. 이 거래 계획은 2025년 5월 9일에 채택되었습니다.

이러한 거래 후 직접적 유권자 보유 주식은 첫 매도 후 197,404주, 두 번째 매도 후 196,089주로 집계되었습니다. 또한 The PVBQ Living Trust를 통해 간접적으로 200,000주를 보유하며 이 신탁의 수탁자로서 단독 의결권과 처분 권한을 행사합니다.

Cadrenal Therapeutics (CVKD) : le PDG/président Quang Pham a signalé des ventes sur le marché libre dans le cadre d'un plan Rule 10b5-1. Le 24/10/2025, il a vendu 1 129 actions ordinaires à un prix moyen pondéré de 14,03 $, avec des transactions allant de 13,99 à 14,10 $. Le 27/10/2025, il a vendu 1 315 actions à un prix moyen pondéré de 13,99 $, avec des transactions entre 13,99 et 14,00 $. Le régime de négociation a été adopté le 9 mai 2025.

Suite à ces transactions, la propriété bénéficiaire directe était de 197 404 actions après la première vente et de 196 089 actions après la seconde. Il détient également 200 000 actions indirectement par le biais de The PVBQ Living Trust, dont il est fiduciaire avec le pouvoir de vote et de disposition exclusif.

Cadrenal Therapeutics (CVKD): CEO/Vorsitzender Quang Pham meldete Open-Market-Verkäufe im Rahmen eines Rule 10b5-1-Plans. Am 24.10.2025 verkaufte er 1.129 Stammaktien zu einem gewichteten Durchschnittspreis von 14,03 USD, mit Geschäften zwischen 13,99 und 14,10 USD. Am 27.10.2025 verkaufte er 1.315 Aktien zu einem gewichteten Durchschnittspreis von 13,99 USD, mit Geschäften zwischen 13,99 und 14,00 USD. Der Handelsplan wurde am 9. Mai 2025 angenommen.

Nach diesen Transaktionen betrug das direkte wirtschaftliche Eigentum nach dem ersten Verkauf 197.404 Aktien und nach dem zweiten 196.089 Aktien. Er hält außerdem indirekt 200.000 Aktien über The PVBQ Living Trust, für den er als Treuhänder mit alleiniger Stimm- und Veräußerungsbefugnis fungiert.

Cadrenal Therapeutics (CVKD): أبلغ الرئيس التنفيذي/الرئيس Quang Pham عن مبيعات في السوق المفتوحة وفق خطة Rule 10b5-1. في 24/10/2025 باع 1,129 سهماً من الأسهم العادية بسعر متوسط مرجح قدره 14.03 دولاراً، وكانت الصفقات تتراوح بين 13.99 و14.10. في 27/10/2025 باع 1,315 سهماً بسعر متوسط مرجح 13.99 دولاراً، وكانت الصفقات بين 13.99 و14.00. تم اعتماد ترتيب التداول في 9 مايو 2025.

بعد هذه المعاملات، بلغت الملكية المحتكرة المباشرة بعد البيع الأول 197,404 سهماً وبعد البيع الثاني 196,089 سهماً. كما يمتلك 200,000 سهم بشكل غير مباشر من خلال The PVBQ Living Trust، الذي يعمل كوصي وله سلطة التصويت والتصرف الحصري.

Positive
  • None.
Negative
  • None.

Cadrenal Therapeutics (CVKD): il CEO/presidente Quang Pham ha riferito vendite in mercato aperto secondo un piano Rule 10b5-1. Il 24/10/2025 ha venduto 1.129 azioni ordinarie a prezzo medio ponderato di 14,03 dollari, con operazioni comprese tra 13,99 e 14,10. Il 27/10/2025 ha venduto 1.315 azioni a prezzo medio ponderato di 13,99 dollari, con operazioni tra 13,99 e 14,00. L'accordo di negoziazione è stato adottato il 9 maggio 2025.

A seguito di queste transazioni, la proprietà diretta beneficiaria era di 197.404 azioni dopo la prima vendita e 196.089 azioni dopo la seconda. Possiede inoltre 200.000 azioni indirettamente attraverso The PVBQ Living Trust, di cui è fiduciario con potere di voto e disposizione esclusivo.

Cadrenal Therapeutics (CVKD): el CEO/presidente Quang Pham reportó ventas en el mercado abierto bajo un plan Rule 10b5-1. El 24/10/2025 vendió 1.129 acciones ordinarias a un precio medio ponderado de 14,03 dólares, con operaciones entre 13,99 y 14,10. El 27/10/2025 vendió 1.315 acciones a un precio medio ponderado de 13,99 dólares, con operaciones entre 13,99 y 14,00. El régimen de negociación se adoptó el 9 de mayo de 2025.

Después de estas transacciones, la titularidad directa beneficiosa fue de 197.404 acciones tras la primera venta y 196.089 acciones tras la segunda. También posee 200.000 acciones indirectamente a través de The PVBQ Living Trust, del cual es fideicomisario con poder de voto y disposición exclusivo.

Cadrenal Therapeutics (CVKD): CEO 겸 의장 Quang Pham은 Rule 10b5-1 계획에 따른 공개시장 매도를 보고했습니다. 2025년 10월 24일에 보통주 1,129주를 가중평균가 14.03달러로 매도했으며 체결가 범위는 13.99~14.10달러였습니다. 2025년 10월 27일에는 1,315주를 가중평균가 13.99달러로 매도했고 체결가 범위는 13.99~14.00달러였습니다. 이 거래 계획은 2025년 5월 9일에 채택되었습니다.

이러한 거래 후 직접적 유권자 보유 주식은 첫 매도 후 197,404주, 두 번째 매도 후 196,089주로 집계되었습니다. 또한 The PVBQ Living Trust를 통해 간접적으로 200,000주를 보유하며 이 신탁의 수탁자로서 단독 의결권과 처분 권한을 행사합니다.

Cadrenal Therapeutics (CVKD) : le PDG/président Quang Pham a signalé des ventes sur le marché libre dans le cadre d'un plan Rule 10b5-1. Le 24/10/2025, il a vendu 1 129 actions ordinaires à un prix moyen pondéré de 14,03 $, avec des transactions allant de 13,99 à 14,10 $. Le 27/10/2025, il a vendu 1 315 actions à un prix moyen pondéré de 13,99 $, avec des transactions entre 13,99 et 14,00 $. Le régime de négociation a été adopté le 9 mai 2025.

Suite à ces transactions, la propriété bénéficiaire directe était de 197 404 actions après la première vente et de 196 089 actions après la seconde. Il détient également 200 000 actions indirectement par le biais de The PVBQ Living Trust, dont il est fiduciaire avec le pouvoir de vote et de disposition exclusif.

Cadrenal Therapeutics (CVKD): CEO/Vorsitzender Quang Pham meldete Open-Market-Verkäufe im Rahmen eines Rule 10b5-1-Plans. Am 24.10.2025 verkaufte er 1.129 Stammaktien zu einem gewichteten Durchschnittspreis von 14,03 USD, mit Geschäften zwischen 13,99 und 14,10 USD. Am 27.10.2025 verkaufte er 1.315 Aktien zu einem gewichteten Durchschnittspreis von 13,99 USD, mit Geschäften zwischen 13,99 und 14,00 USD. Der Handelsplan wurde am 9. Mai 2025 angenommen.

Nach diesen Transaktionen betrug das direkte wirtschaftliche Eigentum nach dem ersten Verkauf 197.404 Aktien und nach dem zweiten 196.089 Aktien. Er hält außerdem indirekt 200.000 Aktien über The PVBQ Living Trust, für den er als Treuhänder mit alleiniger Stimm- und Veräußerungsbefugnis fungiert.

Cadrenal Therapeutics (CVKD): أبلغ الرئيس التنفيذي/الرئيس Quang Pham عن مبيعات في السوق المفتوحة وفق خطة Rule 10b5-1. في 24/10/2025 باع 1,129 سهماً من الأسهم العادية بسعر متوسط مرجح قدره 14.03 دولاراً، وكانت الصفقات تتراوح بين 13.99 و14.10. في 27/10/2025 باع 1,315 سهماً بسعر متوسط مرجح 13.99 دولاراً، وكانت الصفقات بين 13.99 و14.00. تم اعتماد ترتيب التداول في 9 مايو 2025.

بعد هذه المعاملات، بلغت الملكية المحتكرة المباشرة بعد البيع الأول 197,404 سهماً وبعد البيع الثاني 196,089 سهماً. كما يمتلك 200,000 سهم بشكل غير مباشر من خلال The PVBQ Living Trust، الذي يعمل كوصي وله سلطة التصويت والتصرف الحصري.

Cadrenal Therapeutics (CVKD): 首席执行官兼主席 Quang Pham 报告了依据 Rule 10b5-1 计划进行的场外/公开市场销售。 2025年10月24日,他以加权平均价14.03美元出售了1,129股普通股,交易区间为13.99到14.10美元。2025年10月27日,他以加权平均价13.99美元出售了1,315股,交易区间为13.99到14.00美元。该交易安排于2025年5月9日通过。

这些交易之后,第一次出售后直接受益所有权为197,404股,第二次出售后为196,089股。他还通过 The PVBQ Living Trust 间接持有20万股,他在该信托中担任受托人,拥有单独的投票权和处置权。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pham Quang X

(Last) (First) (Middle)
C/O CADRENAL THERAPEUTICS, INC.,
822 A1A NORTH, SUITE 306

(Street)
PONTE VEDRA, FL 32082

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO and Chairman
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/24/2025 S 1,129(1) D $14.03(2) 197,404 D
Common Stock 10/27/2025 S 1,315(1) D $13.99(3) 196,089 D
Common Stock 200,000 I The PVBQ Living Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.10. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
/s/ Matthew K. Szot, Attorney-in-fact 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CVKD’s CEO report on the latest Form 4?

Open‑market sales of common stock executed under a Rule 10b5‑1 trading arrangement adopted on May 9, 2025.

How many CVKD shares were sold and on which dates?

1,129 shares on 10/24/2025 and 1,315 shares on 10/27/2025.

What were the sale prices for the CVKD transactions?

Weighted averages of $14.03 (range $13.99–$14.10) and $13.99 (range $13.99–$14.00).

How many CVKD shares does the reporting person own directly after the sales?

197,404 shares after the 10/24/2025 sale and 196,089 shares after the 10/27/2025 sale.

Does the reporting person have indirect ownership in CVKD?

Yes. 200,000 shares are held indirectly through The PVBQ Living Trust, for which he is trustee.

What is the reporting person’s role at CVKD?

Director, CEO and Chairman, and a 10% owner.
Cadrenal Therape

NASDAQ:CVKD

CVKD Rankings

CVKD Latest News

CVKD Latest SEC Filings

CVKD Stock Data

26.81M
1.51M
27.84%
7.23%
0.55%
Biotechnology
Pharmaceutical Preparations
Link
United States
PONTE VEDRA